Purpose: To assess long-term site-specific risks of second malignancy following non-Hodgkin's lymphoma (NHL) in relation to treatment and demographic factors.
Patients And Methods: A cohort of 2,456 patients with NHL who were first treated from 1973 to 2000 and were younger than 60 years from centers in the British National Lymphoma Investigation were observed, and occurrences of second malignancy was compared with expectations based on general population cancer rates in England and Wales.
Results: In total, 123 second malignancies occurred. Relative risks (RRs) were significantly elevated for all malignancies combined (RR = 1.3; 95% CI, 1.1 to 1.6) and for leukemia (RR = 8.8; 95% CI, 5.1 to 14.1) and lung cancer (RR = 1.6; 95% CI, 1.1 to 2.3). RRs of malignancy overall diminished significantly with increasing age at first treatment. Leukemia risk was significantly increased after chemotherapy (RR = 10.5; 95% CI, 5.0 to 19.3) and mixed-modality treatment (RR = 13.0; 95% CI, 5.2 to 26.7). Relative risks of lung (RR = 1.9; 95% CI, 1.1 to 3.1) and colorectal (RR = 2.1; 95% CI, 1.1 to 3.6) cancers were significantly raised following chemotherapy.
Conclusion: NHL patients are at elevated risk of developing second malignancy, particularly leukemia and lung cancer. The relative risk is greater with patients who are younger at first treatment. Chemotherapy predisposes patients toan increased risk of leukemia, and possibly lung and colorectal cancers. The role of specific drug treatments in the etiology of solid cancers after NHL deserves further investigation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1200/JCO.2005.04.2200 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Relationship between CTF1 gene expression and prognosis and tumor immune microenvironment in glioma.
Eur J Med Res
January 2025
Department of Neurosurgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No 17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, People's Republic of China.
Objective: This study aimed to evaluate CTF1 expression in glioma, its relationship to patient prognosis and the tumor immune microenvironment, and effects on glioma phenotypes to identify a new therapeutic target for treating glioma precisely.
Methods: We initially assessed the expression of CTF1, a member of the IL-6 family, in glioma, using bioinformatics tools and publicly available databases. Furthermore, we examined the correlation between CTF1 expression and tumor prognosis, DNA methylation patterns, m6A-related genes, potential biological functions, the immune microenvironment, and genes associated with immune checkpoints.
Development of a nomogram for predicting malignancy in BI-RADS 4 breast lesions using contrast-enhanced ultrasound and shear wave elastography parameters.
Sci Rep
January 2025
Department of Radiology, The Second Affiliated Hospital of Wannan Medical College, Kangfu Road, Wuhu, 241006, China.
This study aimed to develop a Least Absolute Shrinkage and Selection Operator (LASSO) logistic regression (LR) model using quantitative imaging features from Shear Wave Elastography (SWE) and Contrast-Enhanced Ultrasound (CEUS) to assess the malignancy risk of BI-RADS 4 breast lesions (BLs). The features predictive of malignancy in the LASSO analysis were used to construct a nomogram. Female patients (n = 111) with BI-RADS 4 BLs detected via routine ultrasound at Ma'anshan People's Hospital underwent SWE, CEUS, and histopathological examinations were enrolled in this study.
View Article and Find Full Text PDFSingle-center experience of venetoclax combined with azacitidine in young patients with newly diagnosed acute myeloid leukemia.
Ther Adv Hematol
January 2025
Department of Hematology, The Second Affiliated Hospital of Xi'an Jiaotong University, 157, 5th West Road, Xi'an, Shaanxi 710004, China.
Background: Medical resources, especially blood products, were in short supply during the COVID-19. Less intensive therapy with hypomethylating agents/venetoclax (VEN) seems an effective treatment option for patients with acute myeloid leukemia (AML).
Objectives: To retrospectively analyze the efficacy and safety of VEN combined with azacitidine (AZA) in young adult patients with newly diagnosed (ND) AML.
Comparative analysis of clinicopathological characteristics in young and elderly patients with oral squamous cell carcinoma: a retrospective study in Northeastern Brazil.
Braz Oral Res
January 2025
Universidade Estadual de Campinas - Unicamp, Piracicaba Dental School, Dnepartment of Oral Diagnosis, Piracicaba, SP, Brazil.
The aim of this study was to perform a clinicopathological analysis of oral squamous cell carcinoma (OSCC) in young patients from the northeast of Brazil and compare with elderly individuals. This retrospective study reviewed 104 OSCC cases from 2000 to 2015, focusing on patients under 40 and over 60 at diagnosis. Forty-two patients under 40 years old (40.
View Article and Find Full Text PDFPlatelet indicators do not influence the impact of ABO blood groups on lung adenocarcinoma susceptibility.
Sci Rep
January 2025
Department of Clinical Laboratory, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, People's Republic of China.
The aim of this study was to investigate the role of platelet indicators in the susceptibility of ABO blood groups to lung adenocarcinoma. This was a multicenter retrospective cohort analysis. The study included 528 patients diagnosed with primary lung adenocarcinoma and 528 randomly selected control group patients who were admitted to the Chengdu Fifth People's Hospital from January 2021 to September 2023.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!